トリプルネガティブ乳がん治療の世界市場2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Triple-Negative Breast Cancer Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：MRC2012B1583
• 出版社/出版日：GlobalInfoResearch / 2020年12月28日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、102ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

本調査レポートでは、トリプルネガティブ乳がん治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。トリプルネガティブ乳がん治療の種類別市場規模（アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤）、用途別市場規模（病院薬局、小売薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Celgene、Merck & Co., Inc.、Roche、Immunomedics GmbH、Eisai Co., Ltd、F. Hoffmann-La Roche Ltd、
・地域別グローバル市場分析 2015年-2020年
・トリプルネガティブ乳がん治療の北米市場（アメリカ、カナダ、メキシコ）
・トリプルネガティブ乳がん治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア）
・トリプルネガティブ乳がん治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア）
・トリプルネガティブ乳がん治療の南米市場（ブラジル、アルゼンチン）
・トリプルネガティブ乳がん治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ）
・種類別分析：アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤
・用途別分析：病院薬局、小売薬局
・地域別市場規模予測 2021年-2025年
・調査の結果・結論

Market Overview
The global Triple-Negative Breast Cancer Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Triple-Negative Breast Cancer Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Triple-Negative Breast Cancer Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Triple-Negative Breast Cancer Treatment market has been segmented into:
Alkylating Agents
Plant Products
Microorganism Products
Antimetabolites
Microtubule Stablizing Agents

By Application, Triple-Negative Breast Cancer Treatment has been segmented into:
Hospital Pharmacies
Retail Pharmacies

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Triple-Negative Breast Cancer Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Triple-Negative Breast Cancer Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Triple-Negative Breast Cancer Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Triple-Negative Breast Cancer Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Triple-Negative Breast Cancer Treatment Market Share Analysis
Triple-Negative Breast Cancer Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Triple-Negative Breast Cancer Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Triple-Negative Breast Cancer Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Triple-Negative Breast Cancer Treatment are:
Celgene
Merck & Co., Inc.
Roche
Immunomedics GmbH
Eisai Co., Ltd
F. Hoffmann-La Roche Ltd

レポート目次

Table of Contents

1 Triple-Negative Breast Cancer Treatment Market Overview
1.1 Product Overview and Scope of Triple-Negative Breast Cancer Treatment
1.2 Classification of Triple-Negative Breast Cancer Treatment by Type
1.2.1 Global Triple-Negative Breast Cancer Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Type in 2019
1.2.3 Alkylating Agents
1.2.4 Plant Products
1.2.5 Microorganism Products
1.2.6 Antimetabolites
1.2.7 Microtubule Stablizing Agents
1.3 Global Triple-Negative Breast Cancer Treatment Market by Application
1.3.1 Overview: Global Triple-Negative Breast Cancer Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Global Triple-Negative Breast Cancer Treatment Market by Regions
1.4.1 Global Triple-Negative Breast Cancer Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Triple-Negative Breast Cancer Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Celgene
2.1.1 Celgene Details
2.1.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Celgene SWOT Analysis
2.1.4 Celgene Product and Services
2.1.5 Celgene Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck & Co., Inc.
2.2.1 Merck & Co., Inc. Details
2.2.2 Merck & Co., Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Merck & Co., Inc. SWOT Analysis
2.2.4 Merck & Co., Inc. Product and Services
2.2.5 Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche SWOT Analysis
2.3.4 Roche Product and Services
2.3.5 Roche Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Immunomedics GmbH
2.4.1 Immunomedics GmbH Details
2.4.2 Immunomedics GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Immunomedics GmbH SWOT Analysis
2.4.4 Immunomedics GmbH Product and Services
2.4.5 Immunomedics GmbH Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Eisai Co., Ltd
2.5.1 Eisai Co., Ltd Details
2.5.2 Eisai Co., Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Eisai Co., Ltd SWOT Analysis
2.5.4 Eisai Co., Ltd Product and Services
2.5.5 Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 F. Hoffmann-La Roche Ltd
2.6.1 F. Hoffmann-La Roche Ltd Details
2.6.2 F. Hoffmann-La Roche Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 F. Hoffmann-La Roche Ltd SWOT Analysis
2.6.4 F. Hoffmann-La Roche Ltd Product and Services
2.6.5 F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Triple-Negative Breast Cancer Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Triple-Negative Breast Cancer Treatment Players Market Share
3.2.2 Top 10 Triple-Negative Breast Cancer Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Triple-Negative Breast Cancer Treatment Revenue and Market Share by Regions
4.2 North America Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
5 North America Triple-Negative Breast Cancer Treatment Revenue by Countries
5.1 North America Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
5.2 USA Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6 Europe Triple-Negative Breast Cancer Treatment Revenue by Countries
6.1 Europe Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
6.2 Germany Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.4 France Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue by Countries
7.1 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
7.2 China Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.5 India Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
8 South America Triple-Negative Breast Cancer Treatment Revenue by Countries
8.1 South America Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
8.2 Brazil Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Triple-Negative Breast Cancer Treatment by Countries
9.1 Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Triple-Negative Breast Cancer Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Triple-Negative Breast Cancer Treatment Market Forecast by Type (2019-2024)
10.3 Alkylating Agents Revenue Growth Rate (2015-2025)
10.4 Plant Products Revenue Growth Rate (2015-2025)
10.5 Microorganism Products Revenue Growth Rate (2015-2025)
10.6 Antimetabolites Revenue Growth Rate (2015-2025)
10.7 Microtubule Stablizing Agents Revenue Growth Rate (2015-2025)
11 Global Triple-Negative Breast Cancer Treatment Market Segment by Application
11.1 Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Application (2015-2020)
11.2 Triple-Negative Breast Cancer Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Retail Pharmacies Revenue Growth (2015-2020)
12 Global Triple-Negative Breast Cancer Treatment Market Size Forecast (2021-2025)
12.1 Global Triple-Negative Breast Cancer Treatment Market Size Forecast (2021-2025)
12.2 Global Triple-Negative Breast Cancer Treatment Market Forecast by Regions (2021-2025)
12.3 North America Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.6 South America Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Triple-Negative Breast Cancer Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Triple-Negative Breast Cancer Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Triple-Negative Breast Cancer Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Triple-Negative Breast Cancer Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Celgene Corporate Information, Location and Competitors
Table 6. Celgene Triple-Negative Breast Cancer Treatment Major Business
Table 7. Celgene Triple-Negative Breast Cancer Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Celgene SWOT Analysis
Table 9. Celgene Triple-Negative Breast Cancer Treatment Product and Solutions
Table 10. Celgene Triple-Negative Breast Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Merck & Co., Inc. Corporate Information, Location and Competitors
Table 12. Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Major Business
Table 13. Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Merck & Co., Inc. SWOT Analysis
Table 15. Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Product and Solutions
Table 16. Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Roche Corporate Information, Location and Competitors
Table 18. Roche Triple-Negative Breast Cancer Treatment Major Business
Table 19. Roche Triple-Negative Breast Cancer Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Roche SWOT Analysis
Table 21. Roche Triple-Negative Breast Cancer Treatment Product and Solutions
Table 22. Roche Triple-Negative Breast Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Immunomedics GmbH Corporate Information, Location and Competitors
Table 24. Immunomedics GmbH Triple-Negative Breast Cancer Treatment Major Business
Table 25. Immunomedics GmbH Triple-Negative Breast Cancer Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Immunomedics GmbH SWOT Analysis
Table 27. Immunomedics GmbH Triple-Negative Breast Cancer Treatment Product and Solutions
Table 28. Immunomedics GmbH Triple-Negative Breast Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Eisai Co., Ltd Corporate Information, Location and Competitors
Table 30. Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Major Business
Table 31. Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Eisai Co., Ltd SWOT Analysis
Table 33. Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Product and Solutions
Table 34. Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. F. Hoffmann-La Roche Ltd Corporate Information, Location and Competitors
Table 36. F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Major Business
Table 37. F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Total Revenue (USD Million) (2017-2018)
Table 38. F. Hoffmann-La Roche Ltd SWOT Analysis
Table 39. F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Product and Solutions
Table 40. F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) by Players (2015-2020)
Table 42. Global Triple-Negative Breast Cancer Treatment Revenue Share by Players (2015-2020)
Table 43. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) by Regions (2015-2020)
Table 44. Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Regions (2015-2020)
Table 45. North America Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
Table 46. North America Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Table 47. Europe Triple-Negative Breast Cancer Treatment Revenue (Million USD) by Countries (2015-2020)
Table 48. Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue (Million USD) by Countries (2015-2020)
Table 49. South America Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
Table 50. South America Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Table 51. Middle East and Africa Triple-Negative Breast Cancer Treatment Revenue (Million USD) by Countries (2015-2020)
Table 52. Middle East and Africa Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Table 53. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) by Type (2015-2020)
Table 54. Global Triple-Negative Breast Cancer Treatment Revenue Share by Type (2015-2020)
Table 55. Global Triple-Negative Breast Cancer Treatment Revenue Forecast by Type (2021-2025)
Table 56. Global Triple-Negative Breast Cancer Treatment Revenue by Application (2015-2020)
Table 57. Global Triple-Negative Breast Cancer Treatment Revenue Share by Application (2015-2020)
Table 58. Global Triple-Negative Breast Cancer Treatment Revenue Forecast by Application (2021-2025)
Table 59. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Triple-Negative Breast Cancer Treatment Picture
Figure 2. Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Type in 2019
Figure 3. Alkylating Agents Picture
Figure 4. Plant Products Picture
Figure 5. Microorganism Products Picture
Figure 6. Antimetabolites Picture
Figure 7. Microtubule Stablizing Agents Picture
Figure 8. Triple-Negative Breast Cancer Treatment Revenue Market Share by Application in 2019
Figure 9. Hospital Pharmacies Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Global Triple-Negative Breast Cancer Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Triple-Negative Breast Cancer Treatment Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Triple-Negative Breast Cancer Treatment Revenue Market Share in 2019
Figure 20. Global Top 10 Players Triple-Negative Breast Cancer Treatment Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Regions (2015-2020)
Figure 24. Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Regions in 2018
Figure 25. North America Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 26. Europe Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 28. South America Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 30. North America Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Figure 31. North America Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries in 2019
Figure 32. USA Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Canada Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Europe Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries in 2019
Figure 37. Germany Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 38. UK Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 39. France Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 40. Russia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Italy Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries in 2019
Figure 44. China Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Japan Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Korea Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 47. India Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 49. South America Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Figure 50. South America Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries in 2019
Figure 51. Brazil Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Triple-Negative Breast Cancer Treatment Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 56. UAE Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
Figure 59. Global Triple-Negative Breast Cancer Treatment Revenue Share by Type (2015-2020)
Figure 60. Global Triple-Negative Breast Cancer Treatment Revenue Share by Type in 2019
Figure 61. Global Triple-Negative Breast Cancer Treatment Market Share Forecast by Type (2021-2025)
Figure 62. Global Alkylating Agents Revenue Growth Rate (2015-2020)
Figure 63. Global Plant Products Revenue Growth Rate (2015-2020)
Figure 64. Global Microorganism Products Revenue Growth Rate (2015-2020)
Figure 65. Global Antimetabolites Revenue Growth Rate (2015-2020)
Figure 66. Global Microtubule Stablizing Agents Revenue Growth Rate (2015-2020)
Figure 67. Global Triple-Negative Breast Cancer Treatment Revenue Share by Application (2015-2020)
Figure 68. Global Triple-Negative Breast Cancer Treatment Revenue Share by Application in 2019
Figure 69. Global Triple-Negative Breast Cancer Treatment Market Share Forecast by Application (2021-2025)
Figure 70. Global Hospital Pharmacies Revenue Growth Rate (2015-2020)
Figure 71. Global Retail Pharmacies Revenue Growth Rate (2015-2020)
Figure 72. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Triple-Negative Breast Cancer Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Triple-Negative Breast Cancer Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
Figure 76. Europe Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
Figure 78. South America Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel

以下、関連資料のご紹介

トリプルネガティブ乳がん治療の世界市場（～2026年）

Global Triple-Negative Breast Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04900 2020年11月20日 90Pages
当調査資料はトリプルネガティブ乳がん治療のグローバル市場について調査・分析したレポートです。種類別（アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤）市場規模、用途別（病院薬局、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジ...

HER2陰性乳がん治療の世界市場（～2026年）

Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12176 2020年11月25日 97Pages
当調査資料はHER2陰性乳がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、手術、放射線、ホルモン療法/内分泌療法）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国...

乳癌治療の世界市場（～2026年）

Global Breast Cancer Therapeutic Market Size, Status and Forecast 2020-2026
MRC2-11QY11194 2020年11月25日 96Pages
当調査資料は乳癌治療のグローバル市場について調査・分析したレポートです。種類別（フェーズI治療、フェーズII治療、フェーズIII治療）市場規模、用途別（病院、外来手術センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...

乳がん治療の世界市場2020年：企業別、地域別、種類・用途別

Global Breast Cancer Therapeutic Market 2020 by Company, Regions, Type and Application, Forecast to 2025
MRC2012B0151 2020年12月21日 103Pages
本調査レポートでは、乳がん治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。乳がん治療の種類別市場規模（フェーズI治療、フェーズII治療、フェーズIII治療）、用途別市場規模（病院、外来手術センター、診断センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東...

乳癌スクリーニング検査の世界市場（～2026年）

Global Breast Cancer Screening Tests Market Size, Status and Forecast 2020-2026
MRC2-11QY11193 2020年11月25日 92Pages
当調査資料は乳癌スクリーニング検査のグローバル市場について調査・分析したレポートです。種類別（身体検査、実験室検査、画像検査、遺伝子検査）市場規模、用途別（研究所、癌研究所、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、...

乳癌リキッドバイオプシーの世界市場（～2026年）

Global Breast Cancer Liquid Biopsy Market Size, Status and Forecast 2020-2026
MRC2-11QY11191 2020年11月25日 99Pages
当調査資料は乳癌リキッドバイオプシーのグローバル市場について調査・分析したレポートです。種類別（循環腫瘍細胞（CTC）、無細胞DNA（CfDNA）、細胞外小胞（EV）、その他循環バイオマーカー）市場規模、用途別（病院、診断センター、研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フ...

乳がん予測遺伝子検査の世界市場2020年：企業別、地域別、種類・用途別

Global Breast Cancer Predictive Genetic Testing Market 2020 by Company, Regions, Type and Application, Forecast to 2025
MRC2012B0150 2020年12月21日 108Pages
本調査レポートでは、乳がん予測遺伝子検査の世界市場を広く調査・分析し、今後の市場展望をまとめております。乳がん予測遺伝子検査の種類別市場規模（高浸透性遺伝子、中浸透性遺伝子、低浸透性遺伝子）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南...

転移性がん治療の世界市場（～2026年）

Global Metastatic Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12665 2020年11月25日 91Pages
当調査資料は転移性がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、生物学的標的療法、乳腺手術、ホルモン療法）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

乳がん画像診断装置の世界市場2020年：メーカー別、地域別、種類・用途別

Global Breast Cancer Imaging Diagnostic Equipment Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
MRC2012A1551 2020年12月21日 131Pages
本調査レポートでは、乳がん画像診断装置の世界市場を広く調査・分析し、今後の市場展望をまとめております。乳がん画像診断装置の種類別市場規模（X線装置、コンピューター断層撮影装置、磁気共鳴装置、超音波装置）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国...

乳癌モノクローナル抗体の世界市場（～2026年）

Global Breast Cancer Monoclonal Antibodies Market Size, Status and Forecast 2020-2026
MRC2-11QY11192 2020年11月25日 125Pages
当調査資料は乳癌モノクローナル抗体のグローバル市場について調査・分析したレポートです。種類別（ネイキッドMAb、コンジュゲートMAb）市場規模、用途別（病院、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...

トリプルネガティブ乳がん治療の世界市場（～2026年） Market Analysis and Insights: Global Triple-Negative Breast Cancer Treatment Market The global Triple-Negative Breast Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Triple-Negative Breast Cancer Treat…
HER2陰性乳がん治療の世界市場（～2026年） HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein. Market Analysis and Insights: Global HER2-negative breast ca…
乳癌治療の世界市場（～2026年） Market Analysis and Insights: Global Breast Cancer Therapeutic Market The global Breast Cancer Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Breast Cancer Therapeutic Scope and Market Size Breast Cancer T…
乳がん治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Breast Cancer Therapeutic market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Breast Cancer Thera…
乳癌スクリーニング検査の世界市場（～2026年） Breast cancer is usually a form of tumor that can be visualized through x-ray or felt as a lump. The cancer can be either benign which results in the abnormal growth in the breast area or metastatic that can invade the distant areas of the body. Breast cancer screening is conducted to detect the sig…